Welcome to LookChem.com Sign In|Join Free
  • or
N-(N'-(ethoxycarbonylmethyl)-3-tert-butyl-5-pyrazolyl)-N'-(2,3-dichlorophenyl)urea is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

229003-23-0

Post Buying Request

229003-23-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

229003-23-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 229003-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,9,0,0 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 229003-23:
(8*2)+(7*2)+(6*9)+(5*0)+(4*0)+(3*3)+(2*2)+(1*3)=100
100 % 10 = 0
So 229003-23-0 is a valid CAS Registry Number.

229003-23-0Relevant academic research and scientific papers

1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors

Dumas, Jacques,Hatoum-Mokdad, Holia,Sibley, Robert,Riedl, Bernd,Scott, William J.,Monahan, Mary Katherine,Lowinger, Timothy B.,Brennan, Catherine,Natero, Reina,Turner, Tiffany,Johnson, Jeffrey S.,Schoenleber, Robert,Bhargava, Ajay,Wilhelm, Scott M.,Housley, Timothy J.,Ranges, Gerald E.,Shrikhande, Alka

, p. 2051 - 2054 (2000)

Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-molecule inhibitors of p38 by a combinatorial chemistry effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50 = 13 nM). (C) 2000 Elsevier Science Ltd.

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

-

Page/Page column 33; 62, (2012/03/10)

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

-

Page/Page column 31, (2010/11/28)

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 229003-23-0